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Abstract: Vascular endothelial growth factor A (VEGF-A) is a prominent pro-angiogenic and
pro-permeability factor in the kidney. Alternative splicing of the terminal exon of VEGF-A through
the use of an alternative 3′ splice site gives rise to a functionally different family of isoforms, termed
VEGF-Axxxb, known to have anti-angiogenic and anti-permeability properties. Dysregulation of the
VEGF-Axxx/VEGF-Axxxb isoform balance has recently been reported in several kidney pathologies,
including diabetic nephropathy (DN) and Denys–Drash syndrome. Using mouse models of kidney
disease where the VEGF-A isoform balance is disrupted, several reports have shown that VEGF-A165b
treatment/over-expression in the kidney is therapeutically beneficial. Furthermore, inhibition
of certain splice factor kinases involved in the regulation of VEGF-A terminal exon splicing has
provided some mechanistic insight into how VEGF-A splicing could be regulated in the kidney.
This review highlights the importance of further investigation into the novel area of VEGF-A splicing
in chronic kidney disease pathogenesis and how future studies may allow for the development of
splicing-modifying therapeutic drugs.
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1. Introduction
The human genome is comprised of approximately 20,000 genes, but the human proteome is
estimated to be formed of hundreds of thousands of proteins [1]. This diversity is mainly the result of
a process known as alternative splicing (AS); a single gene transcript can give rise to multiple proteins
depending on the way the gene is spliced [2]. In humans, more than 94% of genes can be alternatively
spliced [3,4]. It is generally accepted that the more evolved a species is, the higher the percentage of
genes that undergo AS [5].
It is becoming increasingly clear that changes to the tightly regulated process of AS in many genes
can result in cellular dysfunction and disease. Cancer is the disease that is most commonly linked to AS
dysregulation [6–8]; however, there are an increasing number of splice isoforms that have been recently
implicated in kidney disease, including vascular endothelial growth factor A (VEGF-A) [9,10]. VEGF-A
is key driver of angiogenesis, permeability, migration, and cell survival [11]. The abnormal expression
of VEGF-A in the kidney has been widely reported in most types of kidney disease [12]. Alternative
splicing of exon 8 of the VEGF-A gene results in the expression of an anti-angiogenic, anti-permeability,
and cyto-protective family of isoforms, termed the VEGF-Axxxb family (the most common isoform
being VEGF-A165b) [13], which has been shown to be protective in kidney disease [9,10].
This review discusses the mechanism of VEGF-A splicing, highlights the importance of a balance
of the VEGF-A exon 8 splice variants in the kidney, and examines the ways in which VEGF-A splicing
can be manipulated to obtain therapeutic benefit.
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2. Alternative Splicing of VEGF-A
2.1. Modes of Alternative Splicing
The process of pre-mRNA AS involves the inclusion/exclusion of whole exons or parts of
exons/introns in the final mRNA transcript. This process is achieved with a splicing reaction conducted
by the spliceosome, a macromolecular assembly composed of small nuclear ribonucleoproteins and
the associated accessory proteins [14]. In brief, the spliceosome assembles at a splice site (a conserved
sequence in the pre-mRNA transcript at the exon-intron junction) and undergoes two transesterification
reactions to achieve splicing. The main modes of AS are: cassette exon skipping or retention, intron
retention, use of an alternative 3′ or 5′ splice sites in exons, and the inclusion/exclusion of two mutually
exclusive exons.
2.2. Regulation of Alternative Splicing
AS is regulated by Cis-acting regulatory elements (auxiliary sequences), which can be divided
into four subgroups; exonic and intronic sequence enhancers (ESEs and ISEs), and exonic and intronic
sequence silencers (ESSs and ISSs). These Cis-acting regulatory elements recruit trans-acting splice
factors to modulate the splicing reaction [2]. Splice factors are RNA-binding proteins, the most common
being serine/arginine-rich (SR) proteins, that act with small nuclear ribonucleoproteins to form and
mediate the action of the spliceosome [15]. Another key family of splice factors are the heterogeneous
ribonucleoproteins (hnRNPs). In general, SR proteins bind to ESEs and recruit core splice factors to the
polypyrimidine tract, activating splicing of a cassette exon, whereas hnRNPs classically block access of
the spliceosome to the polypyrimidine tract, suppressing RNA splicing [16,17]. However, there are
exceptions to these general rules.
2.3. Alternative Splicing of VEGF-A
Human VEGF-A is a major regulator of angiogenesis and vessel permeability [11]. The VEGF-A
gene consists of eight exons and seven introns [18]. AS of VEGF-A can occur through the
inclusion/exclusion of various exons, giving rise to a family of pro-angiogenic isoforms generically
known as VEGF-Axxx (VEGF-A121, VEGF-A145, VEGF-A165, VEGF-A189, and VEGF-A206—the number
denotes the number of amino acids) [19]. It was not until 2002 that a novel alternative 3′ splice site
(distal splice site; DSS) was discovered in exon 8 of the human VEGF-A gene, 66 base pairs downstream
of the canonical proximal 3′ splice site (PSS); use of the DSS creates a new open reading frame and
results in a functionally different family of isoforms, termed the VEGF-Axxxb family [13]. Although the
VEGF-Axxxb isoforms have the same number of amino acids in total, they have an altered C-terminal
sequence that differs by six amino acids (Figure 1). This small change in the terminal six amino
acids results in VEGF-Axxxb having functionally opposite properties to VEGF-Axxx; VEGF-Axxxb
has anti-angiogenic, anti-permeability, and anti-migratory properties [9,10,13,20]. However, like
VEGF-Axxx, VEGF-Axxxb is a pro-survival factor [21].
The most common VEGF-Axxxb isoform in the kidney is VEGF-A165b [22]. The differing
properties of the anti-angiogenic VEGF-A165b are thought to be due to its inability to efficiently
autophosphorylate VEGF receptor 2 (VEGFR-2), the key VEGF-A receptor for driving angiogenesis,
permeability, and migration [20]. Several studies have shown that VEGF-A165b poorly activates the
VEGFR-2 kinase domain, resulting in weak, transient phosphorylation of downstream targets including
Akt and ERK1/2 [10,23].
















The  actions  of  SRSF1  and  SRSF6  on  the  VEGF‐A  pre‐mRNA  are  modulated  by  upstream 
regulators, as summarised  in Figure 2. SRSF1  is a known target of the SR protein kinases 1 and 2 
(SRPK1/2). Inhibition of SRPK1 activity with small molecule inhibitors or RNA interference (RNAi) 
knockdown  of  SRPK1  expression  has  been  reported  to  block  the  phosphorylation  and  nuclear 
shuttling of SRSF1, switching the ratio of VEGF‐A splicing to decrease the pro‐angiogenic VEGF‐Axxx 
and increase the anti‐angiogenic VEGF‐Axxxb isoforms [26,27]. 








Figure 1. Vascular endothelial growth factor A (VEGF-A) splice variants. The VEGF-A pre-mRNA
is comprised of eight exons; inclusion/exclusion of these exons gives ri e to several isoforms with
differing amino acid l ngths. In the terminal exon (exon 8), an alternative 3′ splice s te results in a
new family of isoforms, the VEGF-Axxxb f mily. These isoforms have th same numbe of am o acids
but a di ferent C-terminus sequence, resulting in them being functionally different ( nt -angiogenic).
PSS: proximal spl ce it ; DSS: distal splice si e; UTR: untranslated region.
2.4. Regulation of VEGF-A Exon 8 Splicing
AS of exon 8 of the VEGF-A gene is known to be regulated by several SR proteins. Pre-mRNA
sequence analysis revealed a predicted binding site for Serine/Arginine Rich Splicing Factor 1 (SRSF1)
upstream of the DSS, and a predicted binding site for SRSF6 downstream of the DSS [24]. Binding of
SRSF1 to the pre-mRNA promotes PSS selection, thus resulting in the expression of the VEGF-Axxx
isoforms. On the other hand, binding of SRSF6 to the pre-mRNA promotes DSS selection and the
expression of VEGF-Axxxb isoforms [25].
The actions of SRSF1 and SRSF6 on the VEGF-A pre-mRNA are modulated by upstream regulators,
as summarised in Figure 2. SRSF1 is a known target of the SR protein kinases 1 and 2 (SRPK1/2).
Inhibition of SRPK1 activity with small molecule inhibitors or RNA interference (RNAi) knockdown
of SRPK1 expression has been reported to block the phosphorylation and nuclear shuttling of SRSF1,
switching the ratio of VEGF-A splicing to decrease the pro-angiogenic VEGF-Axxx and increase the
anti-angiogenic VEGF-Axxxb isoforms [26,27].
AS of the VEGF-A terminal exon is understood to be modified by extracellular factors via
signalling cascades, including various growth factors. Insulin-like growth factor 1 (IGF1) and tumour
necrosis factor α (TNFα) have been shown to favour the use of the exon 8 PSS through protein kinase
C (PKC)-induced activation of SRPK1; however, transforming growth factor β (TGFβ) promotes DSS
use through cell division cycle (CDC)-like kinase 1 (Clk1) activation of p38 mitogen-activated kinases
(p38MAPK), which phosphorylates SRSF6 [20,25].
Recent work has focused on small molecule inhibitors of SRPK1, such as SRPIN340, to switch the
splicing of VEGF-A exon 8 to increase the VEGF-A165b/VEGF-A165 ratio for therapeutic use [28,29].
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Within  the glomerulus, VEGF‐A  is a key  regulator of normal  function and  is predominately 
expressed  in high  levels  by mature podocytes, which  cross  the  glomerular  basement membrane 
(GBM)  to  signal  to VEGFR‐2  on  the  glomerular  endothelial  cells  (GEnCs)  (Figure  3)  [30].  In  the 
physiologically  normal  kidney,  despite  high  levels  of  podocyte VEGF‐A  expression,  there  is  no 
angiogenesis. It is thought that the reason for this is that the podocytes express a balance of the pro‐ 
and anti‐angiogenic isoforms of VEGF‐A to maintain normal functioning of the glomerular filtration 
barrier  (GFB)  [21].  In  culture,  podocytes  have  been  shown  to  express  both  VEGF‐A165  and   
VEGF‐A165b mRNA and protein when  in a differentiated state  [22]. Both  isoforms have also been 
shown to be expressed at the mRNA level in the human kidney cortex [9]. 









Figure 2. VEGF-A splicing regulation. Insulin-like growth factor (IGF) activates protein kinase C
(PKC), which in turn phosphorylates SR protei kinase 1 (SRPK1). Activated SRPK1 can then shuttle
the splice factor Serine/Arginine Rich Splicing Factor 1 (SRSF1) to the nucleus, resulting in proximal
splice site (PSS) selection in exon 8 of VEGF-A. The transcription factor Wilms Tumor 1 (WT1) inhibits
the synthesis of SRPK1, downregulating PSS selection. On the other hand, transforming growth factor
(TGF) signalling activates p38 mitogen-activated protein kinases (p38MAPK), which then activate cell
division cycle (CDC)-like kinase 1 (Clk1). Activates Clk1 causes shuttling of the splice factor SRSF6 to
the nucleus, resulting in distal splice site (DSS) selection.
3. VEGF-A Splice Variants in Chronic Kidney Disease
Within the glomerulus, VEGF-A is a key regulator of normal function and is predominately
expressed i high levels by mature podocytes, which cross the glo erular basement membrane (GBM)
to signal to VEGFR-2 on the glomerular endoth lial cells (GEnCs) (Fi ure 3) [30]. In the physiologic lly
normal kidney, despite high levels of podocyte VEGF-A xpression, there is no angiogenesis. I is
thought that the reason for this is that th podocytes express a balance of the pro- and a ti-angiogenic
isoforms of VEGF-A to maintain normal func ion ng of t gl merular filt ation barrier (GFB) [21].
In culture, podocyte have been shown express both VEGF-A165 and VEGF-A165b mRNA and
protein when in a differentiated state [22]. Bot isoforms have also been shown t be expressed at the
mRNA level in the human kidney cortex [9].
Al erations in glomerular VEGF-A expression is implicated is almost every type of kidney disease;
a repor by Marti i et al. [12] highlighted the strong correlat on between VEGF-A expression n the
kidney cortex and the estima ed glomerular filtration rate (eGFR) in patients with a range of chronic
kidn y diseases (CKDs). How ver, it is on y recently that he focus has shifted to assess the expression
of the VEGF-Axxx/VEGF-Axxxb splice varian ratio in CKD. There is evidence to sugg st hat diabetic
ne hropathy (DN) is associated with a switch in VEGF-A splice isoform xpr ssion. Gl merular
samples from DN patients have shown an increase in the expression of VEGF-Axxx mRNA relative to
VEGF-Axxxb mRNA during the later tages of DN, when the k dney function has declined; however,
during the early stages of D , when the kidney i functi ning relatively normally, there is an increase in
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the VEGF-Axxxb/VEGF-Axxx ratio [9]. It is suggested that during the early stages of DN, VEGF-Axxxb








to bind  to VEGFR2 on  the glomerular endothelial cells  (GEnCs), against  the  flow of  filtrate. Upon 
binding  of  VEGF‐Axxx  to  VEGFR2,  the  receptor  is  phosphorylated,  initiating  a  pro‐permeability 
response. However, upon binding of VEGF‐Axxxb  to VEGFR2,  the receptor  is not activated and an 
anti‐permeability response is initiated. 
Another example of the dysregulation of VEGF‐A exon 8 splicing  in CKD  is  in Denys–Drash 
syndrome, where a mutation occurs in the Wilm’s tumour suppression gene, WT1 [31]. In healthy 
podocytes, WT1 binds to the SRPK1 promoter and represses the expression of SRPK1; however, in 










splicing  in  the kidney,  the general  aim  is  to  try  to  switch  the  splicing  ratio  to  increase  the  anti‐
angiogenic VEGF‐Axxxb isoforms, and decrease the pro‐angiogenic VEGF‐Axxx isoforms (summarised 












Figure 3. VEGF-A signalling in the glomerulus. Both VEGF-Axxx (red dots) and VEGF-Axxxb
(green dots) are expressed by the podocytes and diffuse through the glomerular basement membrane
(GBM) to bind to VEGFR2 on the glomerular endothelial cells (GEnCs), against the flow of filtrate.
Upon binding of VEGF-Axxx to VEGFR2, the receptor is phosphorylated, initiating a pro-permeability
response. However, upon binding of VEGF-Axxxb to VEGFR2, the receptor is not activated and an
anti-permeability response is initiated.
Another example of the dysregulation of VEGF-A exon 8 splicing in CKD is in Denys–Drash
syndrome, where a mutation occurs in the Wilm’s tumour suppression gene, WT1 [31]. In healthy
podocytes, WT1 binds to the SRPK1 promoter and represses the expression of SRPK1; however,
in WT1 mutant podocytes, a reduction in VEGF-A165b is observed due to the mutated WT1 not
transcriptionally repressing SRPK1 [26]. This dysregulation of the VEGF-A splicing balance plays a
role in the development of CKD in these patients.
There are several types of ischaemic kidney disease where low VEGF-A expression levels have
been shown to contribute to the pathology, which can be rescued by VEGF administration, such as in
acute kidney injury [32] and renovascular disease [33]. However, there is no reported evidence of the
VEGF-Axxx/VEGF-Axxxb splicing balance/expression levels in these diseases.
4. Manipulation of VEGF-A Splicing as a Potential Therapeutic Avenue in Kidney Disease
As the number of disease entities known to be associated with AS increases, we are beginning
to explore whether manipulation of AS could be used for therapeutic benefit. In terms of VEGF-A
splicing in the kidney, the general aim is to try to switch the splicing ratio to increase the anti-angiogenic
VEGF-Axxxb isoforms, and decrease the pro-angiogenic VEGF-Axxx isoforms (summarised in Figure 4).
There has been promising evidence from both in vitro assays and in vivo models to suggest that
VEGF-A165b is therapeutic in CKD.









VEGF‐Axxxb/VEGF‐Axxx  ratio.  As  such,  they  provide  a  novel  therapeutic  avenue  in  the 
treatment/prevention  of  chronic  kidney  disease.  CKD:  chronic  kidney  disease;  GFR:  glomerular 
filtration rate.   
In mice, podocyte‐specific over‐expression of the pro‐angiogenic VEGF‐A164 has been reported 
to  be  detrimental  to  kidney  function.  Constitutive  over‐expression  of  VEGF‐A164  results  in 
albuminuria at birth and a lack in formation of a fully functional GFB, consistent with the phenotype 




over‐expressed  VEGF‐A165b  in  a  constitutive  manner,  the  functional  phenotype  was  rescued, 
indicating that the balance of VEGF‐A isoforms plays a critical role in the regulation of glomerular 
permeability  [37]. This was also  true with  the dual  insult of  inducible podocyte VEGF‐A164 over‐
expression  and  Streptozotocin  (STZ)‐induced  DN;  constitutive  over‐expression  of  VEGF‐A165b 
prevented the onset of albuminuria in this model [9]. 
Figure 4. Switching VEGF-A splicing with splicing-modifying drugs for therapeutic benefit.
SRPK1 is a key regulator of VEGF-A exon 8 splicing; therefore, it is an ideal target for therapeut c
modulation of VEGF-A splicing to incr ase the VEGF-Axxxb isoform expression. Splicing-modifying
drugs designed to up-regulate WT1 (thus initiating SRPK1 transcriptional repression), i hibit SRPK1
activation or increase the activation/expression of SF6, resulting in a splicing switch to increase
the VEGF-Axxxb/VEGF-Axxx ratio. As such, they provide a novel therapeutic avenue in the
treatment/prevention of chr nic kidney disease. CKD: chronic kidney disease; GFR: glomerular
filtration rate.
In mice, podocyte-specific over-expression of the pro-angiogenic VEGF-A164 has been reported to
be detrimental to kidney function. Constitutive over-expression of VEGF-A164 results in albuminuria
at birth and a lack in formation of a fully functional GFB, consistent with the phenotype of
congenital nephrosis [34,35]. Similarly, inducible over-expression of VEGF-A164 in adult mice
results in glomerular disease characterised by proteinuria, increased glomerular water permeability,
and GFB abnormalities [36,37], although the severity of the disease phenotype remains inconsistent
between different models. When inducible podocyte-specific VEGF-A164 over-expressing mice
also over-expressed VEGF-A165b in a constitutive manner, the functional phenotype was rescued,
indicating that the balance of VEGF-A isoforms plays a critical role in the regulation of glomerular
permeability [37]. This was also true with the dual insult of inducible podocyte VEGF-A164
over-expression and Streptozotocin (STZ)-induced DN; constitutive over-expression of VEGF-A165b
prevented the onset of albuminuria in this model [9].
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On the other hand, low renal expression of VEGF-A has been shown to contribute to disease
pathologies, which can be rescued by VEGF-A administration [32,33]. Although the VEGF-A
isoform expression levels have not been characterised in specific disease types, a mouse model
with podocyte-specific knockdown of VEGF-A has been reported to be detrimental to kidney function.
Heterozygous constitutive knockdown of podocyte VEGF-A resulted in nephrotic syndrome and
end-stage renal disease (ESRD) by 9 weeks of age, whereas homozygous knockdown resulted in
perinatal death [35]. Knockdown of VEGF-A expression in the mature glomerulus has been reported
to result in a range of phenotypes, ranging from profound thrombotic glomerular injury [38], to mild
albuminuria and ultra-structural changes to the GFB [10]. These differences are likely to result from
differing genetic backgrounds and degrees of VEGF-A knockdown. When inducible podocyte-specific
VEGF-A knockdown mice over-expressed the VEGF-A165b isoform in the podocytes, the kidney injury
phenotype was rescued [10]. Our group has recently shown in a quadruple transgenic mouse model
that podocyte-specific overexpression of VEGF-A165b only, while all other VEGF isoforms are deleted,
rescues albuminuria and the increase in water permeability [10].
As described above, DN is associated with dysregulation of VEGF-A splicing. When type I
and type II diabetic mice were treated with intraperitoneal injections of VEGF-A165b recombinant
protein, they did not develop the DN phenotype observed in the diabetic controls [9]. Therefore,
VEGF-A165b appears to play a therapeutic role in mouse models of CKD, indicating that manipulation
of VEGF-A splice isoforms could be a novel therapeutic avenue in CKD. It is important to note that
podocyte-specific VEGF-A165b over-expression alone resulted in no detrimental changes to kidney
function in the long term [39].
A key study examined how the splicing of VEGF-A can be manipulated in cultured WT1 mutant
podocytes. As described above, WT1 mutant podocytes are unable to transcriptionally repress SRPK1
expression, resulting in increased activation of SRSF1 and high expression of the pro-angiogenic
VEGF-A165 with reduced expression of the anti-angiogenic VEGF-A165b. This alteration in VEGF-A
splicing could be reversed by wild-type WT1, a knockdown of SRSF1 or SRPK1, and inhibition of
SRPK1, thus increasing the expression of the anti-angiogenic VEGF-A165b isoform [26].
Podocyte expressed VEGF-A signals to VEGFR-2 located on the GEnCs. Mechanistically, mice
over-expressing podocyte-specific VEGF-A165b have been shown to have an increase in glomerular
VEGFR-2 expression [9]. This is also true for cultured GEnCs treated with VEGF-A165b; however,
unlike VEGF-A165, VEGF-A165b is unable to fully phosphorylate VEGFR2 at the tyrosine residues
required for full activation, resulting in an inhibition in some of the downstream signalling pathways
involved in migration [10]. Interestingly, VEGF-A165b can activate pro-survival factors downstream
of VEGFR2, Akt and ERK1/2 [10], suggesting that VEGF-A165b may either weakly phosphorylate
some tyrosine residues of VEGFR2 in a transient manner, or could be acting through other receptors
such as VEGFR1. Further research is required to gain more information on the mechanistic action of
VEGF-A165b in the kidney.
5. Discussion
The balance of the VEGF-Axxx/VEGF-Axxxb appears to be essential in the normal functioning
of the GFB. This ratio of splice isoforms has been found to be altered in certain types of CKD,
including DN and Denys–Drash syndrome [9,31]. However, manipulation of the pathological balance
of isoforms to increase levels of VEGF-A165b has been shown to have therapeutic benefit via inhibition
of increased angiogenesis and permeability, and through the activation of pro-survival factors [9,10].
This evidence highlights the importance for further investigation into the novel area of the contribution
of VEGF-A splicing towards CKD pathogenesis and how we can manipulate the isoform balance for
therapeutic benefit. We envision that future studies will provide more insights into the mechanistic
aspects of VEGF-A splicing dysregulation in CKD, allowing for the development of a novel class of
splicing-modifying therapeutic drugs.
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